StockData
Achieve Life Sciences, Inc. logo

Achieve Life Sciences, Inc. (ACHV) shareholders

ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as QUIT
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$6.72+0.34 (+5.33%)

Close on Nov 6, 2026Market cap $691.50MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
83M
Shares held, 13F filers
Institutional holders
111
48 new, 17 sold out
Net institutional buying
61M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $175.11K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Jon Winkelried
Joint filing with Tpg Gp A, LLC (12.60%), James G. Coulter (12.60%)
13,755,16012.60%13D (active)Apr 17, 2025
venBio Global Strategic GP V, LLC
Joint filing with venBio Global Strategic Fund V, L.P. (9.99%)
10,737,3179.99%13D (active)Apr 15, 2026
Logos Global Management GP LLC
Joint filing with Logos Global Management LP (9.99%), Arsani William (9.99%) and 5 more
10,538,4409.99%13G (passive)May 11, 2026
Paradigm BioCapital Advisors LP
Joint filing with Paradigm BioCapital Advisors GP LLC (9.20%), Senai Asefaw, M.D. (9.20%) and 1 more
9,903,7129.20%13G (passive)Apr 17, 2026
Franklin Resources, Inc.
Joint filing with Franklin Advisers, Inc. (8.30%)
8,878,9428.30%13G (passive) amendmentJun 30, 2026
Frazier Life Sciences Public Fund, L.P.
Joint filing with Fhmlsp, L.P. (6.50%), Fhmlsp, L.L.C. (6.50%)
6,625,7886.50%13G (passive)Apr 17, 2026
Franklin Advisers, Inc.
Joint filing with Franklin Resources, Inc. (6.20%)
6,369,2526.20%13G (passive) amendmentApr 30, 2026
VHCP Co-Investment Holdings III, LLC
Joint filing with Venrock Healthcare Capital Partners III, L.P. (5.20%), Venrock Healthcare Capital Partners EG, L.P. (5.20%) and 4 more
5,502,0645.20%13G (passive)Apr 17, 2026
JANUS HENDERSON GROUP Ltd.5,502,0645.40%13G (passive)Jun 30, 2026
Vivo Opportunity, LLC5,305,6405.00%13G (passive)Jul 6, 2026
BlackRock, Inc.5,271,3915.10%13G (passive)Jun 30, 2026
Alyeska Fund GP, LLC
Joint filing with Alyeska Investment Group, L.P. (5.60%), Anand Parekh (5.60%)
2,982,7225.60%13G (passive) amendmentSep 30, 2025
Leen Kawas
Joint filing with Propel Bio Management LLC (6.81%), Richard Kayne (6.81%) and 1 more
2,334,1766.81%13G (passive)Mar 4, 2024
Patrick J. Callahan III
Joint filing with Patrick J. Callahan III Trust (9.50%)
2,167,4399.90%13G (passive)Nov 15, 2022

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ACHVValueChange% of portfolio
Frazier Life Sciences Management, L.P.7,614,836–$49.72MNew1.08%
Tpg Gp A, LLC6,877,580–$44.91MNew0.90%
venBio Partners LLC5,914,720–$38.62MNew7.44%
Logos Global Management LP5,425,000–$35.43MNew1.53%
BlackRock, Inc.5,272,017–$34.43M+4,832,6570.00%
Franklin Resources Inc4,953,220–$32.34M+584,0270.01%
Paradigm Biocapital Advisors LP4,951,856–$32.34MNew0.61%
Vanguard Capital Management LLC4,140,812–$27.04M+1,936,0980.00%
Propel Bio Management, LLC4,034,018–$26.34M+247,59313.79%
Marshall Wace, Llp3,770,313–$24.62M+2,751,0320.02%
State Street Corp2,945,526–$19.23M+2,691,0690.00%
Vivo Capital, LLC2,751,032–$17.96MNew1.64%
VR Adviser, LLC2,751,032–$17.96MNew0.54%
Jupiter Topco LLC2,751,032–$17.96MNew0.01%
Eventide Asset Management, LLC2,220,000–$14.50MNew0.19%
Geode Capital Management, LLC2,062,721–$13.47M+1,439,9360.00%
Alyeska Investment Group, L.P.1,925,722–$12.57MNew0.03%
Simplify Asset Management Inc.1,432,105–$9.35M+247,5930.13%
Wellington Management Group Llp1,426,915–$9.32MNew0.00%
LPL Financial LLC902,255–$5.89M+173,8070.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 202611183M48 / 3614 / 1765M3M
Q1 20268122M17 / 1723 / 113M3M
Q4 20257723M24 / 2413 / 109M2M
Q3 20256616M22 / 1719 / 214M15M
Q2 20256526M19 / 2214 / 2616M4M
Q1 20257214M9 / 2121 / 61M3M
Q4 20247016M11 / 2712 / 41M1M
Q3 20246417M13 / 1812 / 33M4M
Q2 20245619M24 / 148 / 95M2M
Q1 20244116M19 / 69 / 714M1M
Q4 2023293M3 / 118 / 90M1M
Q3 2023353M5 / 813 / 80M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

64 funds held ACHV in Q2 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ACHVValue% of fundAs of
Vanguard Total Stock Market Index Fund3,108,369–$20.30M0.00%Jun 30, 2026
Eventide Healthcare & Life Sciences Fund2,220,000–$14.50M0.81%Jun 30, 2026
iShares Russell 2000 ETF1,993,533–$13.02M0.02%Jun 30, 2026
Simplify Propel Opportunities ETF1,432,105–$9.35M12.11%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1,349,858–$8.81M0.08%Jun 30, 2026
Franklin Biotechnology Discovery Fund1,095,791–$7.03M0.61%Jul 31, 2026
Vanguard Extended Market Index Fund957,389–$6.25M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund851,832–$5.47M0.02%Jul 31, 2026
iShares Russell 2000 Growth ETF731,016–$4.77M0.03%Jun 30, 2026
Fidelity Extended Market Index Fund276,242–$1.45M0.00%May 31, 2026
iShares Micro-Cap ETF261,589–$1.71M0.11%Jun 30, 2026
Schwab Small-Cap Index Fund189,138–$1.21M0.02%Jul 31, 2026
Master Small Cap Index Series145,507–$950.16K0.02%Jun 30, 2026
Nuveen Small Cap Blend Index Fund103,456–$664.19K0.02%Jul 31, 2026
Fidelity Total Market Index Fund97,174–$509.19K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Andrew D. GoldbergCEO and President, Director0Apr 21, 2026
Benjamin HalladayChief Financial Officer–Oct 6, 2026
Jerry WanPrincipal Accounting Officer46,764Jan 30, 2026
Mark K. OkiChief Financial Officer127,940Jan 30, 2026
Jaime XinosChief Commercial Officer95,286Jan 30, 2026
Craig DonnellyChief Operations Officer52,372Jan 30, 2026
Mark Lawrence RubinsteinChief Medical Officer39,600Jan 30, 2026
Erik AtkissonChief Legal Officer0Dec 8, 2025
Cindy JacobsPresident & CMO143,214Sep 8, 2025
Richard Alistair StewartDirector209,490Aug 21, 2026
Reid Alexander WaldmanDirector0Jul 29, 2026
Christopher Nathan MartinDirector0Jul 29, 2026
Thomas SelligDirector0Jul 29, 2026
Jeffrey S. FarrowDirector0Jul 29, 2026
Nancy R. PhelanDirector0Jul 29, 2026
Aaron RoystonDirector0Jul 29, 2026
Lucian IancoviciDirector0Apr 24, 2026
Thomas Braxton KingDirector455,000Sep 8, 2025
Bridget A. MartellDirector0Jun 10, 2025
Kristen B. SlaouiDirector0Jun 10, 2025
Stuart DutyDirector0Jun 10, 2025
Tpg Gp A, Llc10% owner–Apr 24, 2026
Jon Winkelried10% owner–Apr 24, 2026
James G. Coulter10% owner6,877,580Apr 24, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Richard Alistair Stewart
Director
Aug 19, 2026Sale−20,626$8.49$175.11K208,249
Richard Alistair Stewart
Chief Executive Officer, Director
Sep 18, 2025Sale−129,501$2.92$378.14K228,875
Richard Alistair Stewart
Chief Executive Officer, Director
Sep 18, 2025Option exercise+297,500––358,376
Mark K. Oki
Chief Financial Officer
Sep 18, 2025Sale−50,060$2.92$146.18K127,940
Mark K. Oki
Chief Financial Officer
Sep 18, 2025Option exercise+168,000––178,000
Cindy Jacobs
President & CMO
Sep 4, 2025Option exercise+110,000––143,214
Cindy Jacobs
President & CMO
Sep 4, 2025Sale−27,629$2.77$76.53K115,585
Jerry Wan
Principal Accounting Officer
Sep 4, 2025Option exercise+34,100––46,764
Jerry Wan
Principal Accounting Officer
Sep 4, 2025Sale−14,070$2.77$38.97K32,694
Thomas Braxton King
Director
Sep 4, 2025Option exercise+455,000––455,000
Thomas Braxton King
Director
Sep 4, 2025Sale−139,858$2.77$387.41K315,142
Jaime Xinos
Chief Commercial Officer
Sep 4, 2025Option exercise+69,000––95,286
Jaime Xinos
Chief Commercial Officer
Sep 4, 2025Sale−20,854$2.77$57.77K74,432
Richard Alistair Stewart
Chieve Executive Officer, Director
Mar 17, 2025Buy+10,000$2.86$28.60K60,876
Mark K. Oki
Chief Financial Officer
Mar 17, 2025Buy+10,000$2.89$28.90K10,000
John Bencich
CEO, Director
Aug 16, 2024Award+5,000$3.67$18.35K100,636
Cindy Jacobs
President & CMO, Director
Aug 16, 2024Award+2,660$3.67$9.76K33,214
Jerry Wan
Principal Accounting Officer
Aug 16, 2024Award+2,857$3.67$10.49K12,664
John Bencich
CEO, Director
Apr 19, 2024Option exercise+25,000––101,724
John Bencich
CEO, Director
Apr 19, 2024Tax withholding−6,088$4.51$27.46K95,636
Jerry Wan
Principal Accounting Officer
Apr 19, 2024Option exercise+5,625––12,057
Jerry Wan
Principal Accounting Officer
Apr 19, 2024Tax withholding−2,250$4.51$10.15K9,807
Richard Alistair Stewart
Executive Chairman, Director
Apr 19, 2024Tax withholding−10,125$4.51$45.66K50,876
Richard Alistair Stewart
Executive Chairman, Director
Apr 19, 2024Option exercise+22,500––61,001
Cindy Jacobs
President & CMO, Director
Apr 19, 2024Tax withholding−3,957$4.51$17.85K30,554
Cindy Jacobs
President & CMO, Director
Apr 19, 2024Option exercise+16,250––34,511
John Bencich
CEO, Director
Mar 4, 2024Buy+10,000$4.59$45.90K76,724
Richard Alistair Stewart
Executive Chairman, Director
Mar 4, 2024Buy+10,000$4.59$45.90K38,501
John Bencich
CEO, Director
May 30, 2023Buy+5,000$5.50$27.50K66,730
Richard Alistair Stewart
Executive Chairman, Director
Apr 28, 2023Tax withholding−2,250$8.29$18.65K28,501
Richard Alistair Stewart
Executive Chairman, Director
Apr 28, 2023Option exercise+5,000––30,751
Jerry Wan
Principal Accounting Officer
Apr 28, 2023Option exercise+1,250––7,101
Jerry Wan
Principal Accounting Officer
Apr 28, 2023Tax withholding−669$8.29$5.55K6,432
Cindy Jacobs
President & CMO, Director
Apr 28, 2023Tax withholding−609$8.29$5.05K18,261
Cindy Jacobs
President & CMO, Director
Apr 28, 2023Option exercise+2,500––18,870
John Bencich
CEO, Director
Apr 28, 2023Option exercise+7,500––63,557
John Bencich
CEO, Director
Apr 28, 2023Tax withholding−1,827$8.29$15.15K61,730
Cindy Jacobs
President & CMO, Director
Apr 21, 2023Tax withholding−3,811$6.80$25.91K16,370
John Bencich
CEO, Director
Apr 21, 2023Tax withholding−5,863$6.80$39.87K56,057
Cindy Jacobs
President & CMO, Director
Apr 21, 2023Option exercise+16,250––20,181
Cindy Jacobs
President & CMO, Director
Apr 21, 2023Tax withholding−4,819$6.80$32.77K15,362
Jerry Wan
Principal Accounting Officer
Apr 21, 2023Option exercise+5,625––8,861
Jerry Wan
Principal Accounting Officer
Apr 21, 2023Tax withholding−3,010$6.80$20.47K5,851
John Bencich
CEO, Director
Apr 21, 2023Tax withholding−7,324$6.80$49.80K54,596
John Bencich
CEO, Director
Apr 21, 2023Option exercise+25,000––61,920
Richard Alistair Stewart
Executive Chairman, Director
Apr 21, 2023Tax withholding−10,125$6.80$68.85K25,751
Richard Alistair Stewart
Executive Chairman, Director
Apr 21, 2023Option exercise+22,500––35,876
John Bencich
CEO, Director
Nov 18, 2022Buy+22,000––36,920
John Bencich
CEO, Director
Aug 16, 2022Award+3,059$4.37$13.37K14,920
Cindy Jacobs
President & CMO, Director
Aug 16, 2022Award+1,817$4.37$7.94K3,931
Jerry Wan
Principal Accounting Officer
Aug 16, 2022Tax withholding−266$4.37$1.16K3,236
Jerry Wan
Principal Accounting Officer
Aug 16, 2022Award+2,827$4.37$12.35K3,502
Jerry Wan
Principal Accounting Officer
Apr 28, 2022Tax withholding−669$7.43$4.97K675
Jerry Wan
Principal Accounting Officer
Apr 28, 2022Option exercise+1,250––1,344
Anthony Clarke
CSO
Apr 28, 2022Tax withholding−250$7.43$1.86K3,502
Anthony Clarke
CSO
Apr 28, 2022Option exercise+1,000––3,752
Cindy Jacobs
President & CMO, Director
Apr 28, 2022Option exercise+2,500––2,723
Cindy Jacobs
President & CMO, Director
Apr 28, 2022Tax withholding−609$7.43$4.52K2,114
Richard Alistair Stewart
Executive Chairman, Director
Apr 28, 2022Tax withholding−2,250$7.43$16.72K13,376
Richard Alistair Stewart
Executive Chairman, Director
Apr 28, 2022Option exercise+5,000––15,626

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
18M shares short
Days to cover
13.6
At 1M shares a day
Change since last report
+1.8%
From 18M shares
Short volume, 20 days
57.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Achieve Life Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 224,923 shares on Aug 21, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Richard Alistair Stewart
Director
Aug 19, 202620,626$155.11KAug 19, 2026Corporate Action

See a number that looks wrong?